Santarus reps pushing Naprelan

Share this article:
Santarus said its sales reps will commence promotional activities in the third quarter for Victory Pharma's Naprelan brand products under a recent co-promotion agreement.

Naprelan tablets are a once daily control-release formulation of the non-steroidal anti-
inflammatory drug (NSAID) naproxen sodium, indicated for pain relief caused by a number of conditions including arthritis.

Santarus said it plans to promote Naprelan to targeted primary care physicians. Reps will also continue to promote the company's Rx heartburn treatment Zegerid to gastroenterologists and primary care doctors alongside reps from inVentiv and Otsuka America.  

Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...